Shots:

• Sosei Heptares receives $37M up front & is eligible to receive ~$694M in development & commercial milestones along with royalties
• The agreement uses Sosei Heptares’ StaR technology & SBDD platform with Lilly’s extensive development, commercialization & therapeutic area expertise for new targets & develops novel treatments for patients
• The collaboration enables Sosei Heptares to focus on multiple GPCR targets (nominated by Lilly) to deliver novel target-selective small molecule candidates for further development & commercialization. Sosei Heptares advances its broad & deep pipeline of novel therapies across multiple therapeutic areas, incl. neurology, immunology, gastroenterology & inflammatory diseases

Ref: Globenewswire | Image: Sosei Heptares